September 23-25, Switzerland

Free Registration, Part of MipTec 2014, Congress Center Basel

FREE DRUG DISCOVERY CONFERENCE IN THE HEART OF EUROPE

MipTec is the largest drug discovery conference in Europe with over 3,000 delegates from pharmaceutical companies

ATTEND 10 OTHER SCIENTIFIC FORUMS AT MIPTEC

Stem Sells, Translational Medicine, Protein Therapeutics, Medicinal Chemistry and others

IN SILICO APPROACHES TO GEROPROTECTOR DISCOVERY AND DRUG REPURPOSING

New in silico approaches to evaluating the efficacy of and repurposing drugs for aging and age-related diseases

MEET YOUNG PROSPECTIVE SCIENTISTS AND RESEARCH MANAGERS

The forum will attract many young scientists in aging research providing the possibility to recruit scarse talent with unique skills and interests

AGING CONFERENCE FOCUSED ON REINVENTINT THE PHARMA INDUSTRY

Unlike other aging conferences, the forum is geared towards the pharmaceutical industry addressing the need for new markers and new drugs within the traditional regulatory frameworks

Tuesday, July 22, 2014

The Former Director of the Human Genome Project from the DOE to present at Aging Pharma

Professor Charles Cantor, the former principal scientist of the Human Genome Project will present at the International Symposium on Geroprotectors: Practical Applications of Aging Research for Drug Discovery on September 23rd.



Dr. Cantor is the chair of the science advisory board of Insilico Medicine, Inc the company using advances in bioinformatics for drug discovery and Retrotope, Inc, the company developing isotopically-fortified organic compounds to combat age-related diseases.

More information on Dr. Cantor is available at www.CharlesCantor.org 

Sunday, July 13, 2014

Novartis to sponsor the Aging Forum

Novartis, one of the top biopharmaceutical companies in the world, will sponsor the Aging Forum at MipTec! This sponsorship is helping the forum to remain FREE TO ATTEND, register and submit abstracts.


The organizers and the delegates would like to thank Novartis for helping advance the area of applied aging research by helping bring together the top though leaders in aging together with the key decision makers in drug discovery and large pharmaceutical companies.

Thursday, May 29, 2014

In the beginning ...


The aging process remains one of the biggest challenges in the biological sciences. Since the advent of recorded human history, we know that countless generations have sought to develop medicines to control it’s outcome. The complexity of biology is more enveloped in this enigma then any disease process that biotech and pharmaceutical company’s labor to develop medicines, because all human beings age - whereas not everyone contract’s a disease.

The drugging-a-disease-mechanism paradigm is a pillar for the drug discovery industry. This is because disease mechanisms are better understood, easier to separate and identify from healthy (normal) biology, and if druggable, can regulate the process to control the disease.  The current pharmaceutical drug discovery process is aligned with the often difficult to navigate healthcare industry, involving many stakeholders and contending parties - before the medicine gets to the patient (even though it is often stated that the “patient is first”).  

Elucidating drugs for aging puts an enormous conundrum before the industry. Is aging a disease or life-style choice? Can we differentiate aging from healthy and normal biology to identify druggable targets? The attention that Big Pharma has now turned to start contemplating medicines for aging, may be a harbinger that some aging symptoms may be possible to medicate for. For example, Novartis released  BYM338 PhaseII results, a drug with FDA-fast track status for Inclusion-body-Myositis (IBM). IBM patients suffer from muscle wasting condition, which could be life threatening.  (see http://www.novartis.com/newsroom/media-releases/en/2013/1723765.shtml).  IBM patients on treatment experienced significant improvement in physical strength compared to placebo. Weakening of muscles is also experienced during the aging process, which limits the quality of life for advanced seniors. Could drugs, like BYM338, be made to target normal muscle weakening as people age?

One of the purposes of this blog is to spotlight “the science of drug discovery” as it applies to longevity, life-span expansion, and in general the hallmarks of the aging process.  Through this portal, we hope to illustrate the issues of drug discovery side of longevity, and invite you, dear reader, to explore and expound these topics with us.

First and foremost, we apologize at the get-go for any errors or omissions (and this includes grammatical and spelling mistakes), because our entrepreneurial enthusiasm to explore, might leave us a bit blind-sided.  “Shoot swiftly, apologize later”  

Best wishes,
Bhupinder Bhullar